Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exo Acquires Medo To Add Sweep AI To Its POCUS Tech

Executive Summary

Medo’s artificial intelligence technology can make ultrasound images significantly easier to interpret and thereby improve the quality of care with Exo’s point-of-care ultrasound.

You may also be interested in...



Exo Bridges Gaps In Ultrasound Diagnostics By Designing Around The Physician User

The company’s Exo Works system integrates with almost any point-of-care ultrasound device – not just Exo’s – to link ultrasound imaging to electronic medical records, hospital picture archiving, and communication systems.

News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests

This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.

Minute Insight: Boston Scientific Walks Away From MI Tech Deal, Citing Regulatory Hurdles

The Federal Trade Commission said it supports Boston Scientific’s decision to walk away from a planned $230m acquisition of Korea-based MI Tech. Boston Scientific said it could not obtain needed global regulatory approvals.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel